IL33 and neoplasm: Indeed, IL-33, as an effective adjuvant in combination with an HPV16 E6/E7-encoded DNA vaccine, exerted anti-tumorigenic function through increased production of IFN-γ+ and TNF-α by antigen-specific CD4+ T cells, and through increasing the concentration of antigen-specific serum IgG, resulting in tumor regression in mice [55].